pain therapeutics inc (PTIE:NASDAQ GS)
pain therapeutics inc (PTIE) Snapshot
|
Open
$3.09
|
Previous Close
$3.08
|
|
|
Day High
$3.10
|
Day Low
$2.85
|
|
|
52 Week High
05/9/13 - $5.57
|
52 Week Low
11/9/12 - $2.06
|
|
|
Market Cap
130.6M
|
Average Volume 10 Days
991.5K
|
|
|
EPS TTM
$-0.08
|
Shares Outstanding
45.3M
|
|
|
EX-Date
12/13/12
|
P/E TM
--
|
|
|
Dividend
--
|
Dividend Yield
26.04%
|
Related News
pain therapeutics inc (PTIE) Related Businessweek News
No Related Businessweek News Foundpain therapeutics inc (PTIE) Details
Pain Therapeutics, Inc., a biopharmaceutical company, develops novel drugs. Its lead drug candidate is REMOXY (oxycodone) Extended-Release Capsules CII, an investigational drug with a controlled release formulation of oxycodone for patients with moderate-to-severe chronic pain. The company’s other product candidates comprise hydromorphone, hydrocodone, and oxymorphone, which are abuse-resistant opioid product candidates. Pain Therapeutics, Inc. has strategic alliance with Pfizer, Inc. to develop and commercialize REMOXY and other abuse-resistant opioid painkillers. The company was founded in 1998 and is based in Austin, Texas.
pain therapeutics inc (PTIE) Top Compensated Officers
pain therapeutics inc (PTIE) Key Developments
Pain Therapeutics Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2013. For the period, the company’s total revenue was $1,958,000 against $2,973,000 a year ago. Operating loss was $443,000 against $148,000 a year ago. Net loss was $408,000 or $0.01 basic and diluted per share against income of $30,000 a year ago.
Pain Therapeutics Inc., Annual General Meeting, May 16, 2013., at 10:00 Central Standard Time. Location: 7801 N Capital of Texas Highway. Agenda: To elect Nadav Friedmann, Ph.D., M.D. and Michael J. O’Donnell as Class I Directors to serve for three-year terms and until their successors are duly elected and qualified; to ratify the selection of Ernst & Young LLP as the independent registered public accounting firm for the company for the fiscal year ending December 31, 2013; to approve, by a non-binding advisory vote, the 2012 executive compensation for the company’s executive officers; and to transact such other business as may properly be brought before the meeting and any adjournments thereof.
On February 11, 2013, the Board of Directors of Pain Therapeutics Inc. appointed Saira Ramasastry to the company’s Board as a Class II director, effective February 11, 2013. The Board also appointed Ms. Ramasastry to the Audit Committee of the Board. In connection with this appointment, the Board determined that Ms. Ramasastry met the qualification requirements for Audit Committee service under NASDAQ Stock Market LLC rules, including determining that she is an independent director under Rule 5605(a)(2) of the Rules and under Rule 10A-3 under the Exchange Act of 1934, as amended. The company amended Article II, Section 1 of the Amended and Restated Bylaws of the company to increase the authorized number of directors constituting the Board to seven.
| Recently Viewed | |||
| PTIE:US | $2.88 USD | -0.20 | |
| Company | Last | Change |
| Hi-Tech Pharmacal Co Inc | $33.81 USD | +0.07 |
| Horizon Pharma Inc | $2.39 USD | +0.01 |
| Neurocrine Biosciences Inc | $12.01 USD | -0.05 |
| Pozen Inc | $4.90 USD | -0.06 |
| Synta Pharmaceuticals Corp | $7.39 USD | -0.12 |
| View Industry Companies | ||
Industry Analysis
PTIE
Industry Average
| Valuation | PTIE | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 13.7x |
|
| Price/Book | 10.2x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 8.3x |
|
Post a JobJobs
- Orlando, FL | Consult SoftPosted: May 22
- New York, NY |Posted: May 17
- San Francisco, CA | YelpPosted: May 02
- San Francisco, CA | YelpPosted: May 02
Sponsored Financial Commentaries
Sponsored Links
To contact PAIN THERAPEUTICS INC, please visit www.paintrials.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.








